Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor David Kavanagh

Newcastle AuthorsTitleYearFull text
Dr Patrick Walsh
Professor David Kavanagh
Atypical Haemolytic Uraemic Syndrome2025
Andrew Bryant
Jan Lecouturier
Giovany Orozco Leal
Dr Vicky Brocklebank
Dr Sonya Carnell
et al.		Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial2025
Professor David Kavanagh
Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis2025
Professor David Kavanagh
Factor B as a therapeutic target for the treatment of complement-mediated diseases2025
Professor David Kavanagh
Kidney Complement Immunohistochemistry in Thrombotic Microangiopathy Subtypes2025
Emily Glover
Professor David Kavanagh
Professor Neil Sheerin
Kidney Transplantation in Patients with aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy2025
Emily Glover
Dr Emma Montgomery
Dr Edwin Wong
Dr Michal Malina
Professor Kevin Marchbank
et al.		Late onset thrombotic microangiopathy in kidney transplants; poor outcome despite eculizumab treatment2025
Dr Katrina Wood
Professor David Kavanagh
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease.2025
Professor David Kavanagh
Dr Edwin Wong
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study2025
Professor David Kavanagh
Post-transplant Thrombotic Microangiopathy2025
Laura Bailey
Vikki Bridgett
Dr Vicky Brocklebank
Dr Sally Johnson
Professor David Kavanagh
et al.		Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis using the United Kingdom RaDaR Registry2025
Giovany Orozco Leal
Professor Luke Vale
Dr Vicky Brocklebank
Andrew Bryant
Dr Thomas Chadwick
et al.		The cost-effectiveness of replacing lifelong therapy of eculizumab with a strategy of disease monitoring for eligible atypical haemolytic uraemic syndrome (aHUS) patients: an economic evaluation of the SETS aHUS trial2025
Dr Kate Smith-Jackson
Dr Patrick Walsh
Dr Gemma Thompson
Dr Beth Gibson
Chloe Connelly
et al.		The membrane attack complex drives the thrombotic microangiopathy in complement mediated aHUS2025
Anneliza Andreadi
Dr Vicky Brocklebank
Dr Patrick Walsh
Professor David Steel
Professor Claire Harris
et al.		The Role of Complement Factor I Rare Genetic Variants in Age Related Macular Degeneration in Finland2025
Professor David Kavanagh
An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group2024
1234567891011